Abdominal Aortic Aneurysm during the Pandemic: Should They Be Operated or Deferred?

Some European societies have recommended deferring the treatment of infrarenal abdominal aortic aneurysm (AAA) ≥5.5 cm during the COVID-19 pandemic. However, these documents have also suggested optimal deferral times, and everything must be adjusted according to the transmission risk/risk of rupture balance.

Intervenir o diferir aneurismas de aorta abdominal en pandemia

Annual risk of rupture can be estimated based on a prospective cohort published by McGuinness et al. Almost 200 patients had regrets about their elective treatment and, after 5 years of follow-up, had rupture rates of 9.5%, 10.2%, and 32.5% for aneurysms of 5.5-5.9 cm, 6-6.9 cm, and ≥7 cm, respectively.

We could assume that perioperative COVID-19-related mortality and community risk are equivalent.

This model calculates the “optimal strategy” (repair or deferral) at different timepoints (3, 6, 9, and 12 months) based on baseline characteristics, risk of rupture, surgical risk, and COVID-19-related mortality risk.

The COVID-19 infection risk was stratified by community virus prevalence and nosocomial transmission (estimated as at least twice the community transmission risk).

Results suggest any aneurysm could be deferred for 3 months.


Read also: La durabilidad del TAVI pasa a un segundo plano con los resultados del TRANSIT.


Surgical repair can be deferred up to 6 months only in young patients (<65 years old) with aneurysms >7cm when the risk of COVID-19 transmission is low.

Endovascular repair (non-open) can be deferred 3 months—or even 6 months—in most scenarios, based on the risk of COVID-19 transmission.

These recommendations support deferral for most patients, but also warn that not everyone will conform to this, and decisions must be made on a case-by-case basis.

PIIS1078588421004524free

Original Title: COVID-19 and abdominal aortic aneurysm intervention: when to defer and when to operate.

Reference: Brenig L. Gwilym et al. European Journal of Vascular & Endovascular Surgery 2021. Journal Pre-proof. https://doi.org/10.1016/j.ejvs.2021.05.034.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

TCT 2024 | SIRONA: Randomized Study Comparing Sirolimus-Coated vs Paclitaxel-Coated Balloon Angioplasty in Femoropopliteal Disease

This prospective, randomized, multicenter, investigator-initiated non-inferiority study compared the use of sirolimus-coated balloon (MagicTouch) vs paclitaxel-coated balloon in endovascular treatment.  The primary objective was to...

TCT 2024 | PEERLESS: Mechanical Thrombectomy with FlowTriever vs Catheter-Directed Thrombolysis in Intermediate Risk PTE

Pulmonary embolism (PE) continues to be the third cause of cardiovascular mortality. The current clinical guidelines recommend anticoagulation in intermediate risk patients presenting right...

Atherosclerotic Renal Artery Stenosis: To Revascularize or Not

At long term, atherosclerotic renal artery stenosis (RAS) can lead to hypertension, chronic kidney disease, and cardiac failure. Historically, these patients have been referred...

Endovascular Management of Chronic TEPH: Is Coronary Management Extrapolatable in This Scenario?

Chronic thromboembolic pulmonary hypertension (CTEPH) is a condition that causes significant functional limitation. Its surgical treatment, known as pulmonary endarterectomy (PEA), has improved the...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...